Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Prager, GW; Lackner, EM; Krauth, MT; Unseld, M; Poettler, M; Laffer, S; Cerny-Reiterer, S; Lamm, W; Kornek, GV; Binder, BR; Zielinski, CC; Valent, P.
Targeting of VEGF-dependent transendothelial migration of cancer cells by bevacizumab.
Mol Oncol. 2010; 4(2): 150-160. [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG


Autor/innen der Med Uni Graz:
Lackner Eva-Maria

Dimensions Citations:

Plum Analytics:
Number of Figures: 4
| | | |
Cancer progression is often associated with the formation of malignant effusions. Vascular endothelial growth factor (VEGF) is a major regulator of vascular permeability and has been implicated as mediator of tumor progression. We examined the production and secretion of VEGF(165) in various primary cancer cells derived from malignant effusions, and the role of exogenous VEGF(165) as a mediator of effusion formation. VEGF(165) was constantly secreted by all cultured tumor cells in an mTOR-dependent manner, as it was inhibited by the mTOR inhibitor rapamycin. Secreted VEGF(165) showed functional activity by inducing endothelial leakiness and tumor cell-transendothelial migration in vitro, effects which could be reverted by the anti-VEGF antibody bevacizumab. Thus, mTOR inhibitors as well as bevacizumab should be considered as potential agents in cancer patients suffering from malignant effusions.
Find related publications in this database (using NLM MeSH Indexing)
Angiogenesis Inhibitors - pharmacology
Antibiotics, Antineoplastic - administration and dosage
Antibodies, Monoclonal - pharmacology
Antibodies, Monoclonal, Humanized -
Apoptosis - drug effects
Cell Culture Techniques -
Cell Line, Tumor -
Cell Movement - drug effects
Endothelium - pathology
Gene Expression Regulation, Neoplastic - drug effects
Humans -
Intracellular Signaling Peptides and Proteins - antagonists and inhibitors
Neoplasms - drug therapy
Protein-Serine-Threonine Kinases - antagonists and inhibitors
Recombinant Proteins - metabolism
Sirolimus - administration and dosage
TOR Serine-Threonine Kinases -
Vascular Endothelial Growth Factor A - antagonists and inhibitors

Find related publications in this database (Keywords)
mTOR protein
© Meduni Graz Impressum